Stay updated with breaking news from Maxcyte Daily. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
MaxCyte, Inc. (NASDAQ:MXCT – Get Free Report) CEO Maher Masoud acquired 70,443 shares of the stock in a transaction dated Monday, June 10th. The stock was bought at an average cost of $4.90 per share, with a total value of $345,170.70. Following the completion of the purchase, the chief executive officer now owns 100,000 shares […]
Cadian Capital Management LP bought a new position in shares of MaxCyte, Inc. (NASDAQ:MXCT – Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 5,644,898 shares of the company’s stock, valued at approximately $26,531,000. MaxCyte comprises 1.1% of Cadian Capital […]
Cadian Capital Management LP acquired a new position in MaxCyte, Inc. (NASDAQ:MXCT – Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 5,644,898 shares of the company’s stock, valued at approximately $26,531,000. MaxCyte comprises about 1.1% of Cadian […]
Valmark Advisers Inc. bought a new stake in MaxCyte, Inc. (NASDAQ:MXCT – Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 83,927 shares of the company’s stock, valued at approximately $394,000. Valmark Advisers Inc. owned about 0.08% of MaxCyte […]
Stephens reaffirmed their overweight rating on shares of MaxCyte (NASDAQ:MXCT – Free Report) in a report published on Tuesday, Benzinga reports. The firm currently has a $11.00 price target on the stock. Several other equities analysts have also recently weighed in on the company. BTIG Research lowered their price target on MaxCyte from $10.00 to […]